AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Zero Candida Ltd specializes in AI-driven medical technology targeting Candidiasis treatment.
- The company is set to begin trading on the TSX Venture Exchange on November 25.
- Its innovative device combines therapy light and a gel-based drug system for effective results.
Zero Candida Ltd (TSXV:ZCT) is poised to begin trading on the TSX Venture Exchange, marking its official debut in the Canadian public markets. The company operates within the healthcare technology sector, focusing on innovative treatments for Candidiasis through advanced AI-powered solutions.
Innovative Medical Technology
The company's core technology is an AI-driven tampon-like device that offers dual functionalities: therapy delivery and real-time data sharing. This device uses a combination of blue light illumination and a gel-based drug delivery system designed to maintain the vaginal pH level, an essential factor in combating Candidiasis. By connecting via Wi-Fi, the device provides healthcare providers with real-time treatment data, enhancing medical oversight.
Advancements in Clinical Development
Zero Candida has made significant progress since its prototype launch in May 2022. The completion of pre-clinical animal studies in September 2023 marks an important milestone, with results confirming the safety of its blue light technology. The company continues refining the device design while advancing its validation processes to meet stringent regulatory requirements.
Regulatory Progress and Market Outlook
The company aims to achieve "Fast Track" approval for its device from the U.S. Food and Drug Administration under the Class II De Novo category. This pathway is critical for accelerating market entry while ensuring compliance with safety and efficacy standards. Recent pre-clinical safety reports have reinforced the potential of the technology, showing no abnormalities or concerns related to its use.
New Market Listing
As Zero Candida Ltd begins trading, its presence on the TSX Venture Exchange underscores its commitment to growth and innovation in healthcare technology. The listing provides a platform to attract attention within the medical device sector and underscores the company's ongoing dedication to addressing critical healthcare challenges.
